Celebrex FAP Study Will Explore Delay Of Surgery In Pediatric Patients

Searle will examine the efficacy of Celebrex for delay of surgery in non-symptomatic adolescent patients with familial adenomatous polyposis, the company told FDA's Oncologic Drugs Advisory Committee Dec. 14.